SCHEMBL4086555

SCHEMBL4086555

N#CCC(c1cccc(S(=O)(=O)N(CCN2CCOCC2)OC(=O)C(F)(F)F)c1)n1cc(-c2ncnc3[nH]ccc23)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYRO3 Q06418 3/20 0.42
AXL P30530 2/20 0.42
MERTK Q12866 1/20 0.42
JAK2 O60674 17/20 0.42
JAK1 P23458 10/20 0.42
JAK3 P52333 3/20 0.42
TYK2 P29597 2/20 0.42
DAPK3 O43293 2/20 0.41
PAK4 O96013 2/20 0.41
ABL1 P00519 2/20 0.41
RET P07949 2/20 0.41
LTK P29376 2/20 0.41
CSNK1A1 P48729 2/20 0.41
CLK2 P49760 2/20 0.41
TNK2 Q07912 2/20 0.41
ROCK1 Q13464 2/20 0.41
DYRK1A Q13627 2/20 0.41
IKBKE Q14164 2/20 0.41
NTRK3 Q16288 2/20 0.41
NTRK2 Q16620 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4088166 0.89 JAK2 (0.48) TYRO3AXLMERTKJAK2JAK1
SCHEMBL16673892 0.88 JAK2 (0.44) TYRO3AXLMERTKJAK2JAK1
SCHEMBL101883 0.86 JAK2 (0.43) TYRO3AXLMERTKJAK2JAK1
SCHEMBL4083273 0.86 JAK2 (0.46) TYRO3AXLMERTKJAK2JAK1
SCHEMBL4087533 0.85 JAK2 (0.47) TYRO3AXLMERTKJAK2JAK1
Trifluoroacetic Acid SCHEMBL4086553 0.84 TYRO3 (0.44) TYRO3AXLMERTKJAK2JAK1
SCHEMBL4093930 0.84 JAK2 (0.44) TYRO3AXLMERTKJAK2JAK1
SCHEMBL100541 0.83 JAK2 (0.51) TYRO3AXLJAK2JAK1JAK3
Trifluoroacetic Acid SCHEMBL4099508 0.83 JAK1 (0.48) TYRO3AXLMERTKJAK2JAK1
SCHEMBL4086240 0.82 JAK2 (0.48) TYRO3AXLMERTKJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130137681-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2013-05-30 US disclosed
US-8415362-B2 Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORPORATION (US) 2013-04-09 US disclosed
US-20090181959-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137681-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 TYRO3 22/4885AXL 403/4885MERTK 222/4885
US-20090181959-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 TYRO3 22/4885AXL 403/4885MERTK 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.